Published in Eur J Pharmacol on August 24, 1993
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther (2014) 0.94
Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures. J Neural Transm (Vienna) (1997) 0.75
Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta (1994) 4.36
Light suppresses melatonin secretion in humans. Science (1980) 3.45
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A (1983) 3.39
Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A (1993) 3.16
Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J (1999) 3.00
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res (1979) 2.61
The purification of beta-galactosidase from Escherichia coli by affinity chromatography. J Biol Chem (1971) 2.58
Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci U S A (1993) 2.41
A phenylethylamine oxidising defect in migraine. Nature (1974) 2.28
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Identification and purification of an adrenal medullary protein (synexin) that causes calcium-dependent aggregation of isolated chromaffin granules. J Biol Chem (1978) 1.98
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Glutaric aciduria; a "new" disorder of amino acid metabolism. Biochem Med (1975) 1.91
Conjugation defect in tyramine-sensitive migraine. Nature (1971) 1.91
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem (1990) 1.86
Multiple forms of rat brain monoamine oxidase. Nature (1969) 1.77
Properties of purified, soluble monoamine oxidase. Can J Biochem (1966) 1.76
Evidence for control of serotonin secretion from human platelets by hydroxyl ion transport and osmotic lysis. Proc Natl Acad Sci U S A (1977) 1.75
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Multiple forms of human brain mitochondrial monoamine oxidase. Nature (1970) 1.69
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
Cloning and sequencing of the human nucleolin cDNA. FEBS Lett (1989) 1.64
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev (1972) 1.56
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature (1984) 1.50
Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc Natl Acad Sci U S A (1996) 1.49
Adenosine triphosphate stimulates inositol phospholipid metabolism and prostacyclin formation in adrenal medullary endothelial cells by means of P2-purinergic receptors. Proc Natl Acad Sci U S A (1987) 1.48
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Self-association of synexin in the presence of calcium. Correlation with synexin-induced membrane fusion and examination of the structure of synexin aggregates. J Biol Chem (1979) 1.45
In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat Biotechnol (2000) 1.45
Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics (1997) 1.44
Theoretical models of the ion channel structure of amyloid beta-protein. Biophys J (1994) 1.44
Internal pH and state of ATP in adrenergic chromaffin granules determined by 31P nuclear magnetic resonance spectroscopy. J Biol Chem (1979) 1.43
2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology (1990) 1.40
The presence of F3-F2a1 dimers and F1 oligomers in chromatin. Biochem Biophys Res Commun (1975) 1.40
Regulation of the transmembrane potential of isolated chromaffin granules by ATP, ATP analogs, and external pH. J Biol Chem (1976) 1.39
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Evidence for stimulation of anion transport in ATP-evoked transmitter release from isolated secretory vesicles. J Biol Chem (1978) 1.37
Role of anions in parathyroid hormone release from dispersed bovine parathyroid cells. Proc Natl Acad Sci U S A (1978) 1.36
The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci (1984) 1.36
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Calcium channel activity of purified human synexin and structure of the human synexin gene. Proc Natl Acad Sci U S A (1989) 1.33
Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J (1996) 1.32
Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. J Neuroimmunol (2001) 1.31
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem (2001) 1.30
Calcium-activated endonexin II forms calcium channels across acidic phospholipid bilayer membranes. J Biol Chem (1990) 1.29
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci U S A (2001) 1.26
Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J (1998) 1.23
Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience (1991) 1.23
Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience (1992) 1.22
Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol (1992) 1.22
Effect of iron chelators on dopamine D2 receptors. J Neurochem (1985) 1.22
Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J (1992) 1.21
An osmotic mechanism for exocytosis from dissociated chromaffin cells. J Biol Chem (1984) 1.21
Promotion of 4-hydroxy-3-methoxyphenylglycol formation in man by reserpine. Nature (1968) 1.19
Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway. Mol Med (2001) 1.16
MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci (1988) 1.16
Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl (1997) 1.16
beta-Amyloid Ca(2+)-channel hypothesis for neuronal death in Alzheimer disease. Mol Cell Biochem (1994) 1.16
A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem (1993) 1.15
Poliovirus induces indoleamine-2,3-dioxygenase and quinolinic acid synthesis in macaque brain. FASEB J (1992) 1.14
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Genomic organization and chromosomal localization of the human nucleolin gene. J Biol Chem (1990) 1.13
The chromaffin granule and possible mechanisms of exocytosis. Int Rev Cytol (1979) 1.12
Intrinsic anion channel activity of the recombinant first nucleotide binding fold domain of the cystic fibrosis transmembrane regulator protein. Proc Natl Acad Sci U S A (1992) 1.12
Membrane fusion protein synexin (annexin VII) as a Ca2+/GTP sensor in exocytotic secretion. Proc Natl Acad Sci U S A (1996) 1.12
Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis. Mol Med (1999) 1.11
Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. Proc Natl Acad Sci U S A (1985) 1.11
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol (1995) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann Neurol (1989) 1.10
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
Muscarinic receptor enhancement of nicotine-induced catecholamine secretion may be mediated by phosphoinositide metabolism in bovine adrenal chromaffin cells. J Biol Chem (1986) 1.09
Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/-) knockout mouse. Proc Natl Acad Sci U S A (1999) 1.09
Membrane capacity measurements suggest a calcium-dependent insertion of synexin into phosphatidylserine bilayers. FEBS Lett (1987) 1.09
Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin. Clin Chem (1987) 1.09
Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature (1972) 1.09
Characterization of branched monounsaturated hydrocarbons of Sarcina lutea and Sarcina flava. Lipids (1971) 1.08
The binding of (14C)phenethylhydrazine to rat liver monoamine oxidase. Biochem Pharmacol (1975) 1.08
Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J Neurochem (1993) 1.07
The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro. Br J Pharmacol (1979) 1.07
Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Adv Biochem Psychopharmacol (1974) 1.07
The ability of amyloid beta-protein [A beta P (1-40)] to form Ca2+ channels provides a mechanism for neuronal death in Alzheimer's disease. Ann N Y Acad Sci (1994) 1.07
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem (1996) 1.07
Simultaneous measurement of plasma 4-hydroxy-3-methoxyphenylethylene glycol and 3,4-dihydroxyphenylethylene glycol by gas chromatography mass spectrometry. Biomed Mass Spectrom (1981) 1.06
Alternative splicing of human synexin mRNA in brain, cardiac, and skeletal muscle alters the unique N-terminal domain. J Biol Chem (1991) 1.06
Real-time measurements of acetylcholine-induced release of ATP from bovine medullary chromaffin cells. FEBS Lett (1985) 1.05
Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation. J Neurochem (1993) 1.05
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid. Brain Res (1992) 1.04
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem (1991) 1.04